meningococcal group a, c, y and w135 polysaccharide conjugate vaccine

This quadrivalent meningococcal conjugate vaccine is designed to provide active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. Developed by Yuxi Watson Biotechnology (a subsidiary of Walvax Biotechnology), the vaccine consists of capsular polysaccharides from each of the four serogroups, each chemically conjugated to a carrier protein, typically CRM197 (a non-toxic mutant of diphtheria toxin). The conjugation process converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which enhances the immune response, particularly in infants and young children, and induces long-term immunological memory. The vaccine was approved in China in 2022 for use in susceptible populations to prevent meningococcal infection.

Brand names

Menway

Other names

MenACYW-CRM197MenACYW-CRM-197MenACYW-CRM 197Quadrivalent meningococcal conjugate vaccineMeningococcal Group A, C, Y and W135 Polysaccharide Conjugate Vaccine (CRM197)